F9 (Factor IX) Gene Mutation Analysis

Hemophilia B

Identification of causative mutations in the factor IX gene for families with hemophilia B can permit very accurate determination of carrier status of at-risk females in these families and provides options for prenatal diagnosis. To identify the mutation in a hemophilia B family, a blood sample is required from an affected individual (proband). Full mutation analysis of the factor IX gene is performed. After a mutation is detected in a proband, carrier testing and prenatal diagnosis may be offered to the family. In cases where a proband is not available for testing, analysis may be performed on a sample from an obligate carrier.

FAQ: Can I test a female for hemophilia A/B?

To open a printable assay summary in a new window, click the link below.

Hemophilia B (Factor IX Gene) Mutation Analysis Assay Summary
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)

Please submit the Test Request Form (TRF) and the Hemophilia Patient Information Form when ordering this test.

Back to the List of Services

NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S.News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.